peripheral pancytopenia. Reduction of medullary hematopoiesis leads to extramedullary hematopoiesis, mainly observed as splenomegaly [2, 3] . Patients may present with a variety of symptoms including night sweats, fatigue and thrombotic events [3] . Average life expectancy is 5 to 7 years. Leukemic transformation into secondary acute myeloid leukemia may be observed to occur in 8 % to 23 % of patients [4, 5] . In addition, metachronous occurrence of other hematologic malignancies including non-Hodgkin lymphoma can be observed [6] . Although such an association of myeloproliferative and lymphoproliferative disorders may occur after cytotoxic drug or radiation exposure, the combination of Hodgkin's lymphoma and post-PV myelofibrosis is exceedingly rare.
This report highlights the potential usefulness of 18 F-FDG PET/CT to correctly identify other more aggressive hematologic malignancies in the context of preexisting myelofibrosis. In recent years, PET/CT using 1 8 F -F D G h a s b e e n i n c r e a s i n g l y u s e d a s a morphofunctional imaging modality for both initial assessment and therapy monitoring in various hematalogic malignancies [7] [8] [9] . Moreover, 18 F-FDG PET/CT is a highly sensitive technique for detection of extramedullary involvement [10] . Bone marrow uptake of 18 F-FDG in myelofibrosis is usually homogeneous [11] , and any lesion with focally increased and inhomogeneous uptake should undergo biopsy for exclusion of leukemic transformation or synchronous lymphoma. This is a case of Hodgkin's lymphoma in the context of myelofibrosis initially detected on 
